Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Rinzimetostat May Limit Prostate Cancer Lineage Plasticity and Restore Therapeutic Targets October 28, 2026
- Newsletter 43/2026 October 25, 2026
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
Harnessing PROTAC Technology: A Novel Approach to Targeting ERG in Prostate Cancer
/in Preclinical Research, PROTACs/by MaxVIR-5500: A Promising T-Cell Engager for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPreclinical: NRM-823, a Breakthrough T-Cell Engager Targeting Advanced Prostate Cancer
/in Immunotherapy, Preclinical Research/by MaxRPT04402 Reactivating PP2A: A Different Approach in Advanced Prostate Cancer Therapy
/in Preclinical Research/by MaxPhase 1b Promising Results: ORIC-944, a PRC2 Inhibitor for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxResults from Phase 3 Trial of CAN-2409: a Promising Immunotherapy for Prostate Cancer
/in Clinical Trial, Localized/by MaxPhase 3 Trial of BMS-986365
/in Clinical Trial, Metastatic, Phase 3/by MaxA New Hope for Aggressive Prostate Cancer: Evexomostat’s Potential
/in Preclinical Research/by Max